RESUMEN
Administration of high-dose vitamin K1 (VK1) overcomes coagulopathy and bleeding elicited by acute poisoning with long-acting anticoagulant rodenticides (LAARs). However, long-term (months) treatment is required due to long LAAR biological half-lives that may lead to poor compliance and recurrent coagulopathy. The half-lives of LAARs are extended by slow metabolism, and similar to warfarin, are thought to undergo enterohepatic recirculation. We now show that treatment with the bile acid sequestrant cholestyramine (CSA) administered concomitantly with VK1 decreases plasma LAAR levels and increases LAAR fecal excretion. Daily CSA treatment for 14 days did not reduce plasma VK1 levels, or increase prothrombin time. Collectively, these data show that CSA accelerates LAAR clearance from rabbits without adverse effects on VK1 anticoagulation, and could provide an additional therapeutic option for treatment of LAAR poisoning.
Asunto(s)
Anticoagulantes , Coagulación Sanguínea , Resina de Colestiramina , Heces , Rodenticidas , Vitamina K 1 , Animales , Conejos , Rodenticidas/farmacocinética , Rodenticidas/sangre , Anticoagulantes/administración & dosificación , Anticoagulantes/farmacocinética , Vitamina K 1/sangre , Vitamina K 1/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Masculino , Heces/química , Semivida , Tiempo de Protrombina , Tasa de Depuración MetabólicaRESUMEN
A 50-year-old man was admitted to the emergency department with abrupt massive epistaxis. An accurate anamnesis and physical evaluation could not reveal any other anomalies, while coagulation tests showed potentially life threatening prolonged prothrombin time, with activated partial thromboplastin and thrombin time, with fibrinogen and antithrombin III within limits. Despite the prompt pharmacological and compressive local treatment, bleeding continued and the patient was therefore hospitalized. Highly specific coagulation and toxicological testing-among others high-performance liquid chromatography assessment on plasma-were performed, leading to the unexpected identification of brodifacoum. Police and criminal justice authorities revealed the source of exposure to brodifacoum after several months of investigation, residing in his everyday life. Brodifacoum is a long-lasting anticoagulant, acting as a vitamin K antagonist, and belongs to the family of superwarfarins. Brodifacoum use is authorized as rodenticide in many countries worldwide, but has been reported as cause of severe coagulopathies in humans, both intentional or involuntary, even consumed as a contaminant of herbal drugs, such as cannabis. The original contribution of this case to the knowledges of human brodifacoum intoxication resides in the multidisciplinary approach and the collaborative interplay of clinical and toxicology experts as well as judicial authorities.
Asunto(s)
4-Hidroxicumarinas/envenenamiento , Accidentes , Anticoagulantes/envenenamiento , Epistaxis/etiología , Medicina Legal , Rodenticidas/envenenamiento , 4-Hidroxicumarinas/sangre , Anticoagulantes/sangre , Cromatografía Líquida de Alta Presión , Homicidio , Humanos , Masculino , Persona de Mediana Edad , Rodenticidas/sangreRESUMEN
Brodifacoum is one of the most widely used rodenticides for rodent control and eradication; however, human and animal poisoning due to primary and secondary exposure has been reported since its development. Although numerous studies have described brodifacoum induced toxicity, the precise mechanism still needs to be explored. Gas chromatography mass spectrometry (GC-MS) coupled with an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was applied to characterize the metabolic profile of brodifacoum induced toxicity and discover potential biomarkers in rat plasma. The toxicity of brodifacoum was dose-dependent, and the high-dose group obviously manifested toxicity with subcutaneous hemorrhage. The blood brodifacoum concentration showed a positive relation to the ingestion dose in toxicological analysis. Significant changes of twenty-four metabolites were identified and considered as potential toxicity biomarkers, primarily involving glucose metabolism, lipid metabolism and amino acid metabolism associated with anticoagulant activity, nephrotoxicity and hepatic damage. MS-based metabonomics analysis in plasma samples is helpful to search for potential poisoning biomarkers and to understand the underlying mechanisms of brodifacoum induced toxicity.
Asunto(s)
4-Hidroxicumarinas/sangre , 4-Hidroxicumarinas/toxicidad , Rodenticidas/sangre , Rodenticidas/toxicidad , Aminoácidos/metabolismo , Animales , Peso Corporal/efectos de los fármacos , Cromatografía Liquida , Análisis Discriminante , Cromatografía de Gases y Espectrometría de Masas , Glucosa/metabolismo , Metabolismo de los Lípidos , Metabolómica , Análisis Multivariante , Análisis de Componente Principal , Ratas Wistar , Espectrometría de Masas en TándemRESUMEN
Severe deficiency of vitamin K-dependent proteins in patients not maintained on vitamin K antagonists is most commonly associated with poisoning by or surreptitious ingestion of warfarin, warfarin-like anticoagulants, or potent rodenticides ("superwarfarins"), such as brodifacoum. Serious bleeding manifestations are common. Superwarfarins are 2 orders of magnitude more potent than warfarin and have a half-life measured in weeks. These rodenticides are readily available household environmental hazards and are sometimes consumed accidentally or as manifestations of psychiatric disease. Immediate diagnosis and proper therapy is critically important to minimize morbidity and mortality because this condition, affecting thousands of patients annually, is reversible. Treatment with large doses of oral vitamin K1, often over months to years, to maintain a near-normal prothrombin time can reverse the coagulopathy associated with superwarfarins. Although these patients initially present to various medical specialties, the hematologist is often consulted to offer the definitive diagnosis and proper therapy.
Asunto(s)
Anticoagulantes/envenenamiento , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Hemorragia/tratamiento farmacológico , Rodenticidas/envenenamiento , Vitamina K/antagonistas & inhibidores , Anciano , Anticoagulantes/sangre , Anticoagulantes/farmacocinética , Trastornos de la Coagulación Sanguínea/complicaciones , Femenino , Hemorragia/etiología , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Rodenticidas/sangre , Rodenticidas/farmacocinéticaRESUMEN
Rare cases of coagulaopathies from dermal absorption of hydroxycoumarin derivatives have been reported. We report the first case of dermal absorption of an indandione derivative rodenticide causing severe coagulopathy. An 18-y-o male worker at a pest exterminating company spilled a concentrated liquid preparation of 0.106% diphacinone in his boot. He did not remove the boot or wash the area for 6 to 8 h. Seven days later he presented to the emergency department with flank pain, hematuria and epistaxis. Laboratory values were PT > 40 sec, PTT > 90, Hb 16.2, and platelets 273. Urinalysis reported gross hematuria with RBCs too numerous to count. Prolonged bleeding was noted at i.v. puncture sites. Initial therapy included i.m. injection of vitamin K and nasal packing. The patient's religious beliefs precluded the use of blood products. The patient was admitted for observation until PT was controlled. He was discharged on high dose vitamin K p.o. dose titrated to the international normalized ratio measured every 48 h. After 2 w, a dose of 100 mg vitamin K/d was set and the patient was followed as an outpatient for 3 mo. Vitamin K therapy was tapered and discontinued 60 d post-exposure with no further elevation in PT. Diphacinone was detected in a serum sample drawn 60 d post-exposure using gradient and isocratic HPLC methods with fluorescence and UV detection. Factors increasing the dermal absorption of the diphacinone were: prolonged skin contact in a confined area and exposure to a concentrated solution.
Asunto(s)
Trastornos de la Coagulación Sanguínea/diagnóstico , Enfermedades Profesionales/diagnóstico , Fenindiona/análogos & derivados , Fenindiona/envenenamiento , Rodenticidas/envenenamiento , Accidentes , Adolescente , Trastornos de la Coagulación Sanguínea/inducido químicamente , Tratamiento de Urgencia , Hematuria/inducido químicamente , Humanos , Masculino , Enfermedades Profesionales/inducido químicamente , Fenindiona/administración & dosificación , Fenindiona/sangre , Rodenticidas/administración & dosificación , Rodenticidas/sangre , Absorción CutáneaRESUMEN
A 23-year-old man was brought to the emergency department after eating four boxes of brodifacoum-containing rodenticide over a 4-day interval and pieces from approximately two bottles of glass over the previous 2 weeks. He was asymptomatic but his prothrombin time was markedly elevated with an international normalized ratio (INR) of 37.8. A plain abdominal film showed diffuse radiopaque foreign bodies, presumably glass, in the large and distal small intestines. Treatment for ingested glass consisted of stool softeners and bulk-forming laxatives. The patient developed mild gingival bleeding and received fresh frozen plasma (FFP) infusions and vitamin K1 orally. At a vitamin K1 dosage of 300 mg/day, the INR corrected to less than 2.0 and the patient was discharged taking that dosage. He returned 26 days later with hematuria and flank pain, and his INR was 189. He was administered FFP and packed red blood cells, and his vitamin K1 dosage was increased to 800 mg/day; his INR returned to baseline. Compliance with taking the vitamin K1, which required ingestion of 60-160 tablets/day, was a serious problem, requiring numerous follow-up calls and visits to the patient at home and work. At 5-month follow he was doing well. Compliance with large daily doses of vitamin K1 for treatment of "superwarfarin" ingestion may be poor because of the duration of treatment and large number of pills required. A more concentrated formulation may be advantageous for management of patients with brodifacoum poisoning.
Asunto(s)
4-Hidroxicumarinas/envenenamiento , Trastornos de la Coagulación Sanguínea/inducido químicamente , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Deglución , Vidrio , Rodenticidas/envenenamiento , Vitamina K 1/uso terapéutico , 4-Hidroxicumarinas/administración & dosificación , 4-Hidroxicumarinas/sangre , Adulto , Embalaje de Medicamentos , Humanos , Relación Normalizada Internacional , Masculino , Cooperación del Paciente , Rodenticidas/administración & dosificación , Rodenticidas/sangre , Vitamina K 1/administración & dosificación , Vitamina K 1/farmacocinéticaRESUMEN
Ingestion of long-acting anticoagulant rodenticides such as brodifacoum can lead to prolonged and life-threatening coagulopathy. A paucity of conflicting information is available on brodifacoum's half-life and elimination pharmacokinetics. In addition, the optimal dose, duration, and route of administration of vitamin K(1) therapy are unknown. We report the case of a 52-year-old man who ingested eight 43-g boxes of a rodenticide (d-Con Mouse-Prufe II; 0.005% brodifacoum; Reckitt & Colman, Wayne, NJ). This case demonstrates that after stabilization with fresh frozen plasma, high-dose oral vitamin K(1) therapy ( congruent with 7 mg/kg per 24 hours divided every 6 hours) was effective in treating brodifacoum-induced coagulopathy. The concentration of vitamin K(1) required for normal coagulation in this case was less than the accepted value of 1 microg/mL, which is derived from a rabbit model. In this case, brodifacoum appears to follow zero-order elimination pharmacokinetics. In future cases of patients with ingestions of long-acting anticoagulants who present with coagulopathy, it may be useful to obtain serial brodifacoum concentrations to determine elimination curves to help predict the duration of oral vitamin K(1) therapy.